Protara Therapeutics, Inc.
TARA · XNASCIK 1359931fmd_0TJ0ZX8AY4VJAAP81KTSN7KCNS制造业 · 生物制品（不含诊断试剂）模板: 标准
覆盖范围: 2012年1月01日 至 2026年9月30日，共 56 个期间
| 项目 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| 营业总收入 | – | – | – | – | – | – | – | – | – | – |
| 净利息收入 | – | – | – | – | (0) | – | – | – | – | – |
| 净投资收益 | – | – | – | – | – | – | 0 | – | – | – |
| 已实现投资收益（损失） | – | – | – | – | – | – | 0 | 0 | – | 0 |
| 研发费用 | 19 | 22 | 12 | 4 | 12 | 21 | 17 | 25 | 32 | 43 |
| 营业费用合计 | 29 | 30 | 21 | 8 | 34 | 47 | 67 | 44 | 49 | 65 |
| 营业利润 | (29) | (30) | (21) | (8) | (34) | (47) | (67) | (44) | (49) | (65) |
| 利息费用 | – | – | – | – | 0 | 0 | – | – | – | – |
| 利息及投资收益 | – | – | – | – | 1 | 0 | 1 | 3 | 4 | 6 |
| 其他营业外收入（支出） | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 3 | 5 | 7 |
| 税前利润 | (29) | (30) | (21) | (15) | – | – | – | – | 45 | 57 |
| 所得税费用 | – | – | – | – | – | – | – | – | – | – |
| 持续经营净利润 | – | – | – | – | – | – | – | – | – | – |
| 净利润 | (29) | (30) | (21) | (8) | (34) | (47) | (66) | (40) | (45) | (57) |
| 归属于普通股股东的净利润 | (29) | (37) | (21) | – | 34 | 47 | (66) | (40) | – | – |